Boehringer Ingelheim (BI) announced today the final analysis of the REVERSE-AD data, which reinforced the safety and efficacy of its FDA-approved anticoagulant reversal agent. The findings were presented in a late-breaking session at the International Society on Thrombosis and Haemostasis (ISTH) in Berlin, and simultaneously published in the New England Journal of Medicine. A press release from BI with additional study details is available here.